PAUL A. BUNN Jr., M.D.; KENNETH A. FOON, M.D.; DANIEL C. IHDE, M.D.; DAN L. LONGO, M.D.; JOYCE EDDY, R.N.; CHARLES F. WINKLER, M.D.; STEPHEN R. VEACH, M.D.; JACOB ZEFFREN, M.D.; STEVEN SHERWIN, M.D.; ROBERT OLDHAM, M.D.
High-dose recombinant leukocyte A interferon (50 X 106 U/m2 body surface area, intramuscularly, three times weekly) was tested in a clinical trial involving patients with advanced cutaneous T-cell lymphomas to determine its effectiveness and toxicity. All 20 patients had advanced stages of disease refractory to two or more standard therapies. Objective partial remissions lasting 3 months to more than 25 months (median, 5 months) were documented in 9 patients. The major dose-limiting toxicity was a severe influenza-like syndrome with malaise, anorexia, depression, weight loss, and decreased performance status; this effect was reversible after dose reductions in all patients and did not recur with re-escalation of doses in 10 patients. This interferon preparation is highly effective in the treatment of advanced refractory cutaneous T-cell lymphomas, and new schedules to reduce toxicity and achieve complete responses, combined treatment with chemotherapy or serotherapy, and its use in earlier stages of disease should be investigated.
BUNN PA, FOON KA, IHDE DC, LONGO DL, EDDY J, WINKLER CF, et al. Recombinant Leukocyte A Interferon: An Active Agent in Advanced Cutaneous T-Cell Lymphomas. Ann Intern Med. ;101:484–487. doi: 10.7326/0003-4819-101-4-484
Download citation file:
Published: Ann Intern Med. 1984;101(4):484-487.
Results provided by:
Copyright © 2019 American College of Physicians. All Rights Reserved.
Print ISSN: 0003-4819 | Online ISSN: 1539-3704
Conditions of Use